These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8015584)

  • 1. More on the GUSTO trial.
    Topol EJ; Califf RM; Lee KL
    N Engl J Med; 1994 Jul; 331(4):277-8. PubMed ID: 8015584
    [No Abstract]   [Full Text] [Related]  

  • 2. Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Eisenberg C
    Pharmacotherapy; 1997; 17(4):850-2. PubMed ID: 9250573
    [No Abstract]   [Full Text] [Related]  

  • 3. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study.
    Krumholz HM; Gross CP; Peterson ED; Barron HV; Radford MJ; Parsons LS; Every NR
    Am Heart J; 2003 Nov; 146(5):839-47. PubMed ID: 14597933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Jeremiah Metzger lecture. Thrombolysis and dilatation in coronary occlusion.
    Ross RS
    Trans Am Clin Climatol Assoc; 1987; 98():151-66. PubMed ID: 2956749
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of the GUSTO trial's main conclusion--author's reply. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Stringer KA
    Pharmacotherapy; 1997; 17(5):1043. PubMed ID: 9324198
    [No Abstract]   [Full Text] [Related]  

  • 8. Once more with GUSTO.
    Jaffe AS
    Contemp Intern Med; 1993 Jul; 5(7):9-13. PubMed ID: 10171969
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue plasminogen activator.
    de Bono DP
    Br J Hosp Med; 1986 Aug; 36(2):87. PubMed ID: 3091129
    [No Abstract]   [Full Text] [Related]  

  • 10. Tissue-type plasminogen activator for acute coronary thrombosis.
    Med Lett Drugs Ther; 1987 Dec; 29(754):107-9. PubMed ID: 3119965
    [No Abstract]   [Full Text] [Related]  

  • 11. On 'jumbo' and 'junkie' trials. A fumbled affair, a jungle, or the ultimate solution?
    Hugenholtz PG
    Eur Heart J; 1991 Feb; 12(2):101-2. PubMed ID: 1904349
    [No Abstract]   [Full Text] [Related]  

  • 12. Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations.
    Krucoff MW; Green CL; Langer A; Klootwijk LJ; Trollinger KM; Sawchak ST; Wilderman NM; Veldkamp RF; Pope JE; Simoons ML
    J Electrocardiol; 1993; 26 Suppl():249-55. PubMed ID: 8189133
    [No Abstract]   [Full Text] [Related]  

  • 13. [Canadian Consensus Conference on Coronary Thrombolysis--current aspects].
    Cairns J; Armstrong P; Belenkie I; Hirsh J; Johnstone D; Knudtson M; Lemieux M; Massel D; Naylor D; Roy L
    Can J Cardiol; 1995; 11(7):581-6. PubMed ID: 7656193
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator (t-PA). Will it fulfill its promise?
    Sherry S
    N Engl J Med; 1985 Oct; 313(16):1014-7. PubMed ID: 3930959
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS; Avins AL
    Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations].
    Ardashev VN; Sokolianskiĭ NV; Bystrov VV
    Klin Med (Mosk); 2000; 78(12):28-30. PubMed ID: 11210347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant tissue plasminogen activator: implications in therapy.
    Topol EJ
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):25-31. PubMed ID: 2508227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.